Your help is needed to fulfill a very important Food and Drug Administration requirement to assess prescribers' and pharmacists' understanding of the iPLEDGE® Program and the safe use of isotretinoin. This assessment is being conducted via a Knowledge, Attitudes, and Behavior (KAB) survey through February 28, 2019.
Invitations to participate in the KAB survey will be sent throughout the survey window to a random sample(s) of prescribers and pharmacists. Should you receive an invitation, please understand that your participation is encouraged and very much appreciated.
Thank you in advance for your support of this very important effort.
The upgrades to the iPLEDGE® Program system are complete.
Note: There are no changes to the iPLEDGE Program safety requirements with the new system enhancements.
For patients, iPLEDGE Program website has a new look and feel. All iPLEDGE Program safety requirements and patient functionality remains unchanged.
For prescribers and designees, there are some enhancements for managing patients, including enhanced patient search functionality.
The enhancements to the iPLEDGE Program system will also require prescribers, upon initial login, to:
Failure to supply these identifiers may result in the prescriber's patients' prescriptions not being authorized for dispensing.
The iPLEDGE Program system will allow Pharmacy Network Connectivity (the switch).
If your pharmacy wants to continue to obtain a Risk Management Authorization to dispense isotretinoin via the web site, www.ipledgeprogram.com, or the automated phone system, 1-866-495-0654, no further action is required.
Have Questions? Call our toll-free number 1-866-495-0654